Popular investor Cathie Wood’s ARK Invest made key portfolio moves on Monday, September 15, 2025, with the spotlight on a major sell in the AI healthcare space. As per ARK’s daily trade disclosures, the largest transaction of the day was a sale in Tempus AI (TEM). At the same time, the fund continued to build its stake in biotech company Arcturus Therapeutics (ARCT).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wood Extends Selling in Tempus AI
On Monday, the ARK Genomic Revolution ETF (ARKG) sold 7,270 shares of Tempus AI, the largest trade of the day. The transaction was valued at roughly $627,982. Tempus AI is a healthcare technology company that uses artificial intelligence to improve clinical decision-making.
This sale marks another step in ARK’s steady reduction of Tempus AI exposure in recent sessions. It followed a smaller trim on Friday, when the fund offloaded 2,636 shares valued at $234,024. The repeated trimming could signal a cautious stance toward the company’s near-term outlook, or it may simply reflect a broader portfolio rebalance.
Wall Street’s Take on TEM
On TipRanks, Tempus AI stock has a Moderate Buy consensus rating based on six Buy and six Hold ratings. Also, the average TEM price target of $75.09 implies an 11.79% downside potential from current levels. Year-to-date, TEM stock has gained 152%.
Wood Boosts Biotech Bet with Arcturus Purchase
On the buy side, ARK continued to build its stake in Arcturus Therapeutics. The fund purchased 27,408 shares through the ARKG ETF valued at about $474,706. This follows Friday’s buy of 25,710 shares valued at roughly $463,808.
Arcturus is a biotech company that develops RNA-based medicines. The continued purchases show ARK is increasing its stake and growing more confident in the company.
What Is the Price Target for ARCT?
On TipRanks, Arcturus Therapeutics stock has a Strong Buy consensus rating based on 10 unanimous Buy ratings. Furthermore, the average ARCT price target of $61.75 implies a 240.6% upside potential from current levels. Year-to-date, Arcturus Therapeutics stock has gained 7%.
